Published in Cancer Weekly, June 8th, 2004
The randomized study will assess efficacy, overall safety, and tolerability of the combination in two different dosing schedules. VELCADE is also being investigated in a range of phase I and II solid and hematologic tumors. It is currently approved in the United States for the treatment of patients with relapsed and refractory multiple myeloma and is also approved in Europe for the same...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.